Literature DB >> 8856793

The diverse pathogenic potential of anti-DNA antibodies from various sources to induce experimental systemic lupus erythematosus.

M Swissa1, A Lerner, T Sasaki, E Sela, M Blank, Y Shoenfeld.   

Abstract

It has previously been shown that immunization with pathogenic anti-DNA idiotypes (Ids; e.g. 16/6 Id) leads to the induction of experimental system lupus erythematosus (SLF) in naive mice. The disease is characterized by serological (e.g. anti-double-strand DNA), clinical (elevation of erythrocyte sedimentation rate, leukopenia and proteinuria) and histological (immune complex deposition in kidneys) parameters. To determine whether the 16/6 Id carrying anti-DNA antibodies has unique pathogenic ability, in the current study we have employed diverse sources of anti-DNA antibodies to induce experimental SLE. An IgM anti-DNA antibody lacking the 16/6 Id was able to induce the production of the serological markers of experimental SLE, but not the clinico-histological findings. Furthermore, an IgA anti-DNA (16/6 Id derived from the serum of a patient with celiac disease was very effective in inducing the whole presentation of experimental SLE. Other anti-DNA antibodies failed to induce the autoimmune condition. Combined with our previous experience, the current study points to the diverse potential of various anti-DNA antibodies to induce SLE. The 16/6 Id is only one of a list of the potent pathogenic anti-DNA Ids. These facts may explain in part the diversity of clinical presentations of SLE, including asymptomatic subjects who carry high serum titers of anti-DNA antibodies.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8856793     DOI: 10.1159/000164003

Source DB:  PubMed          Journal:  Pathobiology        ISSN: 1015-2008            Impact factor:   4.342


  1 in total

1.  The thrombophilic network of autoantibodies in celiac disease.

Authors:  Aaron Lerner; Nancy Agmon-Levin; Yinon Shapira; Boris Gilburd; Sandra Reuter; Idit Lavi; Yehuda Shoenfeld
Journal:  BMC Med       Date:  2013-04-04       Impact factor: 8.775

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.